Skip to main content
. 2023 Nov 15;14:1279496. doi: 10.3389/fimmu.2023.1279496

Figure 4.

Figure 4

Quantification of the indicated human serum-derived small EV subpopulation as defined by the small EV marker CD9 plus custom anti-CD14 and anti-CD61 on ExoView® Tetraspanin Chips. (A) CD9+CD14+ small EV counts in polytrauma (ISS ≥ 15, within 24 h post-trauma) with internal organ damage (polytrauma OD) vs. polytrauma without internal organ damage (polytrauma w/o OD). (B) CD9+CD61+ small EV counts in small EVs in polytrauma OD vs. polytrauma w/o OD. (C) CD9+CD14+CD61+ small EV counts in small EVs in polytrauma OD vs. polytrauma w/o OD. Statistical significance was assessed by a two-tailed, unpaired t-test (*p < 0.05; **p < 0.01; ***p < 0.001; (A) t = 6.248, df = 59; (B) t = 5.100, df = 59; (C) t = 4.679, df = 59). All these scatter dot plots show lines at the median with a 95% CI. Post-hoc calculated power (1 − β err prob) is 1.0. Including corresponding AUROC, sensitivity, specificity, and cut-off values. CFU, centrifugal filter unit; EV, extracellular vesicle; ISS, injury severity score; AUROC, area under the receiver operating characteristic curve.